Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to announce it has signed an exclusive license agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd (OTCMKTS: SKHHY) for the use and commercialization of the Company's PromarkerD test for diabetic kidney disease in the United States. Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to announce it has signed an exclusive license agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd (OTCMKTS: SKHHY) for the use and commercialization of the Company's PromarkerD test for diabetic kidney disease in the United States. Under the agreement, Sonic Healthcare USA will be offering PromarkerD to physicians and healthcare systems through its client engagement teams across the US...

This week, Sonic Healthcare USA (Sonic) began testing for Monkeypox (MPXV), using the Centers for Disease Control and Prevention (CDC) Non-variola Orthopoxvirus, high complexity NAAT (RT-PCR) molecular assay...

Sonic Healthcare USA (Sonic) was selected as one of five commercial laboratories authorized by the US Department of Health and Human Services (HHS)...

SARS-CoV-2 Omicron Variant of Concern

LMC Pathology Services (LMC), a Sonic Healthcare USA Anatomic Pathology Practice, is the first reference laboratory in the United States to offer the VENTANA MMR RxDx...

Sonic Healthcare USA is announced as a Laboratory Testing Partner for National K-12 School Testing Program

Sonic Healthcare USA has launched a multiplex RT-PCR assay that combines testing for SARS-CoV-2 (COVID-19) and Influenza A/B with a single specimen collection.

Today, Sonic Healthcare USA (Sonic) was awarded a contract from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Advanced Technology Platforms (RADx-ATP) initiative.

A new validation study published today, “Thyroid Cytology Smear Slides: An Untapped Resource for ThyroSeq Testing."

Over the last few weeks, our network of clinical laboratories throughout the United States has seen a significant increase in demand for COVID-19 molecular testing.